Background
Methods
Patients
Diagnosis and staging systems
Treatment and response
Statistic analysis
Results
Clinical characteristics
Characteristics |
N (%) | 5-year RFS |
P value | 5-year OS |
P value | |
---|---|---|---|---|---|---|
Age (years) | <=60 | 64 (63) | 90.2 ± 4.2 % | 0.040 | 91.8 ± 3.9 % | 0.037 |
>60 | 37 (37) | 69.2 ± 9.3 % | 67.0 ± 9.8 % | |||
Sex | Male | 57 (56) | 89.1 ± 4.6 % | 0.244 | 90.7 ± 4.4 % | 0.234 |
Female | 44 (44) | 75.4 ± 7.6 % | 74.1 ± 8.0 % | |||
B symptoms | No | 57 (56) | 79.1 ± 6.2 | 0.190 | 79.7 ± 6.5 % | 0.193 |
Yes | 44 (44) | 88.2 ± 5.6 % | 87.6 ± 5.8 % | |||
Extranodal involvement | Single site | 85 (84) | 87.2 ± 4.3 % | 0.040 | 87.8 ± 4.4 % | 0.018 |
Multiple sites | 16 (16) | 66.0 ± 12.4 % | 63.6 ± 13.2 % | |||
LDH | Normal | 77 (76) | 89.0 ± 4.3 % | 0.011 | 90.9 ± 4.0 % | 0.009 |
Abnormal | 24 (24) | 63.9 ± 11.0 % | 63.6 ± 11.1 % | |||
β2-MG | Normal | 50 (50) | 94.1 ± 4.1 % | 0.034 | 93.2 ± 4.7 % | 0.025 |
Abnormal | 51 (50) | 74.4 ± 6.7 % | 75.9 ± 6.7 % | |||
Hypoalbuminemia | No | 76 (75) | 87.5 ± 4.4 % | 0.036 | 88.3 ± 4.6 % | 0.025 |
Yes | 25 (25) | 70.3 ± 10.3 % | 67.9 ± 11.0 % | |||
Anemia | No | 56 (55) | 89.3 ± 4.5 % | 0.144 | 91.1 ± 4.3 % | 0.129 |
Yes | 45 (45) | 73.8 ± 8.1 % | 71.8 ± 8.6 % | |||
Site of origin | Gastric | 48 (47) | 90.6 ± 5.2 % | 0.012 | 92.8 ± 5.0 % | 0.008 |
Duodenum and small bowel | 17 (17) | 74.0 ± 13.2 % | 70.7 ± 14.3 % | |||
Ileocecal | 16 (16) | 86.7 ± 8.8 % | 86.7 ± 8.8 % | |||
Colorectal | 15 (15) | 84.0 ± 10.6 % | 82.1 ± 11.7 % | |||
Combined | 5 (5) | 40.0 ± 21.9 % | 40.0 ± 21.9 % |
Surgical approaches and chemotherapy
Pathological characteristics
Characteristics |
N (%) | 5-year RFS |
P value | 5-year OS |
P value | |
---|---|---|---|---|---|---|
Tumor morphology | Ulcerative type | 12 (12) | 87.5 ± 11.7 % | 0.251 | 87.5 ± 11.7 % | 0.244 |
Diffuse type | 18 (18) | 68.0 ± 12.0 % | 66.7 ± 12.4 % | |||
Massive type | 71 (70) | 86.9 ± 4.7 % | 88.1 ± 4.6 % | |||
Depth of invasion | Mucosa/submucosa | 0 | – | 0.022 | – | 0.029 |
Muscularis propria/subserosa | 40 (40) | 95.8 ± 4.1 % | 94.7 ± 5.1 % | |||
Beyond serosa (visceral peritoneum) without invasion of adjacent structures | 43 (42) | 71.3 ± 8.1 % | 73.7 ± 8.0 % | |||
Involvement of adjacent structures or organs | 18 (18) | 81.1 ± 9.9 % | 80.4 ± 10.2 % | |||
Involvement of regional lymph nodes | Negative | 48 (48) | 90.8 ± 5.1 % | 0.038 | 89.4 ± 6.0 % | 0.048 |
Positive | 53 (52) | 75.8 ± 6.7 % | 77.8 ± 6.5 % | |||
Invasion to adjacent structures or organs | No | 79 (78) | 87.8 ± 4.4 % | 0.024 | 86.5 ± 4.8 % | 0.028 |
Yes | 22 (22) | 69.4 ± 10.5 % | 73.6 ± 10.2 % | |||
High level of Ki-67 | Negative | 76 (75) | 90.1 ± 3.8 % | <0.001 | 91.3 ± 3.8 % | <0.001 |
Positive | 25 (25) | 52.6 ± 14.4 % | 48.0 ± 14.5 % | |||
Bcl-2 expression | Negative | 53 (52) | 97.8 ± 2.2 % | <0.001 | 97.6 ± 2.4 % | <0.001 |
Positive | 48 (48) | 65.8 ± 8.2 % | 65.8 ± 8.7 % |
Treatment outcome
Treatment |
N
| 5-year RFS |
P value | 5-year OS |
P value |
---|---|---|---|---|---|
Radical surgery | 74 | 88.5 ± 4.4 % | 0.004 | 87.7 ± 4.8 % | 0.004 |
Alleviate surgery | 27 | 69.5 ± 9.7 % | 72.3 ± 9.7 % | ||
Radical surgery and chemotherapy with Rituximab | 44 | 93.8 ± 4.3 % | 0.302 | 93.3 ± 4.6 % | 0.333 |
Radical surgery and chemotherapy without Rituximab | 21 | 88.2 ± 7.8 % | 88.2 ± 7.8 % | ||
Alleviate surgery and chemotherapy with Rituximab | 16 | 92.9 ± 6.9 % | 0.002 | 91.7 ± 8.0 % | 0.001 |
Alleviate surgery and chemotherapy without Rituximab | 8 | 58.3 ± 18.6 % | 71.4 ± 17.1 % |
Staging systems
Staging system | Stage |
N (%) | 5-year RFS |
P value | 5-year OS |
P value | |
---|---|---|---|---|---|---|---|
Ann Arbor staging with Musshoff modification | I (Ie1–Ie2) | 62 (61) | 86.8 ± 5.1 % | 0.423 | 87.6 ± 5.3 % | 0.428 | |
II (IIe1–IIe2) | 39 (52) | 77.9 ± 7.4 % | 76.1 ± 7.7 % | ||||
IPI | Low | 65 (64) | 89.4 ± 4.5 % | 0.006 | 90.9 ± 4.4 % | 0.004 | |
L–I | 19 (19) | 93.8 ± 6.1 % | 93.8 ± 6.1 % | ||||
H–I | 4 (4) | 56.3 ± 14.8 % | 55.6 ± 14.9 % | ||||
High | 13 (13) | 50.0 ± 2.5 % | 50.0 ± 2.5 % | ||||
Lugano classification | Early stage (I–II) | 82 (81) | 86.5 ± 4.5 % | 0.039 | 85.4 ± 4.9 % | 0.044 | |
Late stage (IIE) | 19 (19) | 71.1 ± 11.0 % | 76.0 ± 10.5 % | ||||
Paris staging system | T | 1 | 0 | – | 0.022 | – | 0.029 |
2 | 40 (40) | 95.8 ± 4.1 % | 94.7 ± 5.1 % | ||||
3 | 43 (42) | 71.3 ± 8.1 % | 73.7 ± 8.0 % | ||||
4 | 18 (18) | 81.1 ± 9.9 % | 80.4 ± 10.2 % | ||||
N | 0 | 48 (48) | 93.5 ± 4.5 % | <0.001 | 92.2 ± 5.4 % | <0.001 | |
1 | 51 (50) | 75.0 ± 6.9 % | 77.2 ± 6.7 % | ||||
2 | 2 (2) | 50.0 ± 35.4 % | 50.0 ± 35.4 % | ||||
3 | 0 | – | – | ||||
M | 0 | 95 (94) | 85.9 ± 4.2 % | 0.018 | 86.2 ± 4.3 % | 0.020 | |
1 | 6 (6) | 50.0 ± 20.4 % | 50.0 ± 20.4 % | ||||
2 | 0 | – | – |